[PDF] Top 20 Duloxetine in the treatment of major depressive disorder: an open label study
Has 10000 "Duloxetine in the treatment of major depressive disorder: an open label study" found on our website. Below are the top 20 most common "Duloxetine in the treatment of major depressive disorder: an open label study".
Duloxetine in the treatment of major depressive disorder: an open label study
... of treatment-emergent abnormal labo- ratory values was ...acute-phase treatment, 37/377 patients ...had treatment-emergent abnormal ALT during acute phase therapy, 1 patient ...sponding ... See full document
11
Continuation treatment of major depressive disorder: is there a case for duloxetine?
... Abstract: Duloxetine is a serotonin–noradrenaline reuptake inhibitor with established efficacy for the short-term treatment of major depressive ...continuation treatment (greater than ... See full document
13
Efficacy and Safety of Vortioxetine and Duloxetine 60 mg Compared Placebo for the Treatment of Major Depressive Disorder: A Systematic Review and Meta Analysis
... Background: Major depressive disorder is a serious public health problem affecting the lives of millions in the worldwide and leading causes of disability and ...This study aimed to eva- luate ... See full document
10
Treatment patterns associated with Duloxetine and Venlafaxine use for Major Depressive Disorder
... retrospective study was conducted using data extracted from a large nationwide US administrative claims data- base (PharMetrics Integrated Outcomes Database) dating from July 2004 through July ... See full document
10
Escitalopram vs duloxetine in acute treatment of major depressive disorder: meta-analysis and systematic review
... venlafaxine. Duloxetine (Dul), another selec- tive noradrenaline reuptake inhibitor, has shown its efficacy in the treatment for MDD ...the treatment of MDD is ... See full document
9
An observational study of duloxetine versus SSRI monotherapy in Japanese patients with major depressive disorder: subgroup analyses of treatment effectiveness for pain, depressive symptoms, and quality of life
... on treatment outcome by duloxetine or SSRIs, patients were stratified by their HAM-D17 baseline ...with duloxetine presented overall more improvement in BPI-SF scores compared with patients receiving ... See full document
10
Treatment discontinuation and tolerability as a function of dose and titration of duloxetine in the treatment of major depressive disorder
... Second, we compared arms across Groups 1 and 2 to assess the impact of maximum dose on DCAE. These two studies had many similar factors that may justify our compari- son: clinical trial phase, target disease, and its ... See full document
9
Duloxetine in the treatment of Major Depressive Disorder: A comparison of efficacy in patients with and without melancholic features
... Melancholic patients are less likely to respond to non-spe- cific supportive therapies, such as cognitive behavior ther- apy or interpersonal psychotherapy, and more often require pharmacotherapy to achieve a successful ... See full document
12
Multimodal functional and structural neuroimaging investigation of major depressive disorder following treatment with duloxetine
... longitudinal treatment studies have most frequently investigated the serotonin reuptake inhibitors (SRI), in which reduced activity in subcortical and limbic regions in MDD patients has been noted following ... See full document
11
Duloxetine for the long-term treatment of Major Depressive Disorder in patients aged 65 and older: an open-label study
... long-term, open- label treatment with duloxetine (80 mg/d or 120 ...of duloxetine (60 mg once daily (QD)) in patients aged 55 years and older ...which duloxetine demonstrated ... See full document
10
Comparative Effect of Collaborative Care, Pain Medication, and Duloxetine in the Treatment of Major Depressive Disorder and Comorbid (Sub)Chronic Pain : Results of an Exploratory Randomized, Placebo-Controlled, Multicenter Trial (CC:PAINDIP)
... on treatment efect ...a treatment group consisting of CC including duloxetine, but no pain management program, to examine whether a pain management program increases treatment efect on top of ... See full document
14
Twelve-month, prospective, open-label study of repetitive transcranial magnetic stimulation for major depressive disorder in partial remission
... this study. Response to treatment was defined using the Clinical Global Impression-Improvement (CGI-I) with at least moderate ...The study protocol was approved by the local ethics committee and all ... See full document
5
Effectiveness and cost effectiveness of transmural collaborative care with consultation letter (TCCCL) and duloxetine for major depressive disorder (MDD) and (sub)chronic pain in collaboration with primary care: design of a randomized placebo controlled multi Centre trial: TCC:PAINDIP
... solving treatment (PST), both effective in the treatment of depression ...the treatment if pain and depres- sion coexist, as well as selective serotonin and noradre- nalin reuptake inhibitors (SNRIs) ... See full document
14
Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder
... mg/day, duloxetine 40–60 mg/day, or mirtazapine 15–45 ...therapy treatment and were not allowed to switch antidepressant medications during the course of open-label ...the ... See full document
10
Predictors of remission in the treatment of major depressive disorder: real-world evidence from a 6-month prospective observational study
... observational study identify a number of potential predictors of remission in the treatment of MDD in the Middle East, East Asia, and Mexico, where such information is very ...and treatment with ... See full document
9
Desvenlafaxine in the treatment of major depressive disorder
... At this stage in the life of DVS, it is diffi cult to evaluate its role over the next decade in the treatment of MDD. As with other SNRIs, the drug should be prescribed once a day. In the United States where the ... See full document
10
Comparative clinical profile of mirtazapine and duloxetine in practical clinical settings in Japan: a 4-week open-label, parallel-group study of major depressive disorder
... with duloxetine in patients with major depressive disorder ...of duloxetine (n = ...and duloxetine treatment groups (P = ...and duloxetine significantly improved ... See full document
6
Agomelatine as monotherapy for major depression: an outpatient, open-label study
... this study was to assess the antidepressant efficacy, safety, and the influence of agomelatine on the functioning of patient in common clinical ...this open-label, 8-week, multicenter, Phase IV ... See full document
10
Xenon in the treatment of panic disorder: an open label study
... investigator-initiated study was performed under a prospective clinical trial protocol approved by the Institute of Mental Health and Addictology, which is accredited by the Ministry of Health of the Russian Fed- ... See full document
10
Duloxetine in the management of diabetic peripheral neuropathic pain
... This study was an open- label design consisting of two ...on duloxetine 60 mg/day (after a 1-week 30 mg/day lead-in) for 7 weeks (weeks ...their duloxetine dose increased to 120 mg/day ... See full document
14
Related subjects